CUPERTINO, Calif., May 1, 2023
/PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced
that it will report its first quarter 2023 financial results and
host a conference call after the market close on Monday, May 8, 2023.
Monday, May 8 @ 4:30pm Eastern Time / 1:30pm Pacific Time
Toll Free:
1-877-869-3847
International:
201-689-8261
Conference ID: 13738577
Webcast:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=nKLHIvLR
About DURECT Corporation
DURECT is a
biopharmaceutical company committed to transforming the treatment
of acute organ injury and chronic liver diseases by advancing novel
and potentially lifesaving therapies based on its endogenous
epigenetic regulator program. Larsucosterol (also known as
DUR-928), DURECT's lead drug candidate, binds to and inhibits the
activity of DNA methyltransferases (DNMTs), epigenetic enzymes
which are elevated and associated with hypermethylation found in
alcohol-associated hepatitis (AH) patients. Larsucosterol is in
clinical development for the potential treatment of AH, for which
FDA has granted a Fast Track Designation; non-alcoholic
steatohepatitis (NASH) is also being explored. In addition,
POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid
analgesic utilizing the innovative SABER® platform technology, is
FDA-approved and has been exclusively licensed to Innocoll
Pharmaceuticals for development and commercialization in the
United States. For more
information about DURECT, please visit www.durect.com and
follow us on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statements
This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, relating to: the development and
commercialization of POSIMIR by Innocoll, the potential to develop
larsucosterol for AH, NASH or other indications, and the potential
benefits, if any, of DURECT's product candidates. Actual results
may differ materially from those contained in the forward-looking
statements contained in this press release, and reported results
should not be considered as an indication of future performance.
The potential risks and uncertainties that could cause actual
results to differ from those projected include, among other things,
the risk that Innocoll may not commercialize POSIMIR successfully,
the risk that the AHFIRM trial takes longer to conduct than
anticipated due to COVID-19 or other factors, the risk that ongoing
and future clinical trials of larsucosterol do not confirm the
results from earlier clinical or pre-clinical trials, or do not
demonstrate the safety or efficacy of larsucosterol in a
statistically significant manner, and risks related to the
sufficiency of DURECT's cash resources, DURECT's anticipated
capital requirements and capital expenditures, DURECT's need or
desire for additional financing, DURECT's ability to obtain capital
to fund its operations and expenses and DURECT's ability to
continue to operate as a going concern. Further information
regarding these and other risks is included in DURECT's most recent
Securities and Exchange Commission (SEC) filings, including its
annual report on Form 10-K for the year ended December 31, 2022 under the heading "Risk
Factors." This report is available on DURECT's website at
www.durect.com under the "Investors" tab and on the SEC's website
at www.sec.gov. All information provided in this press release and
in the attachments is based on information available to DURECT as
of the date hereof, and DURECT assumes no obligation to update this
information as a result of future events or developments, except as
required by law.
NOTE: POSIMIR® is a trademark of Innocoll
Pharmaceuticals Limited in the U.S. and a trademark of DURECT
Corporation outside of the U.S. SABER® is a trademark of
DURECT Corporation. Other referenced trademarks belong to their
respective owners. Larsucosterol (DUR-928) is an investigational
drug candidate under development and has not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities for any indication.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-first-quarter-2023-financial-results-and-provide-business-update-on-may-8-301812453.html
SOURCE DURECT Corporation